On January 1, 2024, Patrick Lin, Chief Business - Strategy Officer of Processa Pharmaceuticals, Inc. [PCSA], completed a stock transaction involving the company's common stock. Lin executed a sale of 539 shares at a price of $2.79 per share, resulting in a total transaction value of $1,503.81. This transaction was part of a disposal activity described as payment of exercise price or tax liability by delivering or withholding securities. Additionally, Lin acquired 1,675 shares through the exercise or conversion of derivative security, which did not have a reported transaction price. Following these transactions, Lin's direct holdings in Processa Pharmaceuticals common stock amounted to 28,614 shares.

On January 1, 2024, Patrick Lin, Chief Business - Strategy Officer of Processa Pharmaceuticals, Inc. [PCSA], completed a stock transaction involving the company's common stock. Lin executed a sale of 539 shares at a price of $2.79 per share, resulting in a total transaction value of $1,503.81. This transaction was part of a disposal activity described as payment of exercise price or tax liability by delivering or withholding securities. Additionally, Lin acquired 1,675 shares through the exercise or conversion of derivative security, which did not have a reported transaction price. Following these transactions, Lin's direct holdings in Processa Pharmaceuticals common stock amounted to 28,614 shares.